Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corsair Gaming Inc (CRSR) vs Davita Inc (DVA) Price & Performance

Corsair Gaming IncTrade
Davita IncTrade

Price performance (Past 24H)

Key statistics

Corsair Gaming Inc vs Davita Inc — how do they compare? Corsair Gaming Inc trades at $13.22 (market cap $1.42B), while Davita Inc trades at $175.04 (market cap $11.29B). The key difference: Davita Inc is far larger — about 8× Corsair Gaming Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Davita Inc for 113 Days on average.

CRSRDVA
Market Cap
$1.42B$11.29B
Volume
1,160,938582,204
Sector
TechnologyHealth
52-Week High
$14.35$240.96
52-Week Low
$4.58$103.87
Typical Hold Time
25 Days113 Days
Enterprise Value
$1.41B$24.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $13.59, down slightly by 0.37% on the day. The stock exhibits a bullish technical signal with recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. Revenue for 2025 was $1.47 billion, though net income was negative $16.16 million. The company launched new products like the VOXARA microphone and acquired Trak Racer assets, signaling growth initiatives. Analyst consensus is a 'Hold' with a price target of $12.40, below the current price, indicating caution despite positive momentum.

The outlook for CRSR is mixed; strong earnings performance and product innovation offer upside, but valuation concerns and negative net income pose risks. Investors should weigh the bullish technical trends and recent institutional interest against the high P/E ratio of 42.23 and analyst price targets suggesting limited near-term gains. Key risks include competitive pressures and execution challenges in the gaming hardware market.

Davita Inc

DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.

The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRSR
0% Buy100% Sell
Avg holding period · 25 Days
DVA
91% Buy9% Sell
Avg holding period · 113 Days

Top news

Latest headlines on both assets

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR →

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →